Machine signal
Active cluster sell — 3 distinct insiders, $6.3M, window ends Jul 29, 2026.
Figures computed from official regulatory filings — .
Analysttarget 94.82 USD (+217%) · consensus 4.55/5 · 18 buy · 2 hold · 0 sell
Ownershipinsiders 2.84% · institutions 60.61% · short 20.5% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Viking Therapeutics, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Market information source · Oct 5, 2026
SEC company identity · Oct 5, 2026
Open-market timeline · full history
12 buys112 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Kelly-Gemmell Dorothy Elizabeth | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Kelly-Gemmell Dorothy Elizabeth | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| ZANTE GREG | Sell | $710.1K | SEC |
| Lian Brian | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Lian Brian | Sell | $4.9M | SEC |
| Mancini Marianna | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Mancini Marianna | Sell | $609.6K | SEC |
| ZANTE GREG | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Chen Hubert C | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Aubuchon Neil William | Buy | $149.9K | conv 68First in 12mo | SEC |
| Aubuchon Neil William | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| ZANTE GREG | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Lian Brian | Sell | $224.4K | SEC |
| ZANTE GREG | Sell | $352.7K | SEC |
| FOEHR MATTHEW Wtrack record | Sell | $561.8K | SEC |
| FOEHR MATTHEW Wtrack record | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| FOEHR MATTHEW Wtrack record | Exercise | $53.3K | SEC |
| Lian Brian | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Mancini Marianna | Sell | $1M | SEC |
| Lian Brian | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Mancini Marianna | Sell | $453.8K | SEC |
| MACARTNEY LAWSON | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Lian Brian | Sell | $1.8M | SEC |
| Mancini Marianna | Sell | $56.1K | SEC |
| ZANTE GREG | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |